Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Silvia Antolín1 Medical Oncology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain, [email protected]Correspondence[email protected]

Benigno Acea2 Surgery Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

Luis Albaina2 Surgery Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

Ángel Concha3 Anatomic Pathology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

Paz Santiago3 Anatomic Pathology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

Tomás García-Caballero4 Department of Morphological Sciences, University of Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

Joaquín J Mosquera5 Radiology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

José Ramón Varela5 Radiology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

Rafaela Soler5 Radiology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain

Lourdes Calvo1 Medical Oncology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain, [email protected]

Your download is now in progress and you may close this window